INOVIO PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
INOVIO PHARMACEUTICALS, INC. (INO) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of -$13.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-06-30 was -$13.90M.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2026-03-31 was -$4.10M.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-12-31 was $21.19M.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2025-09-30 was -$22.50M.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2025 was $493.00K, a 82.39% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2024 was $2.80M.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2020 was -$75.67M, a 4390.58% decline from fiscal 2019.
- INOVIO PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2019 was $1.76M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month as first filed | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$13.90M 10-Q · filed 2026-08-12 | -$18.00M 10-Q · filed 2026-08-12 | $3.19M derived: sum of 3 quarters · filed 2026-08-12 | -$19.31M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | -$4.10M 10-Q · filed 2026-05-13 | $17.09M derived: sum of 2 quarters · filed 2026-05-13 | -$5.41M derived: sum of 3 quarters · filed 2026-05-13 | -$7.31M derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.31M derived: sum of 2 quarters · filed 2026-03-12 | -$3.21M derived: sum of 3 quarters · filed 2026-08-12 | $493.00K 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$22.50M 10-Q · filed 2025-11-10 | -$24.40M derived: sum of 2 quarters · filed 2026-08-12 | -$20.70M 10-Q · filed 2025-11-10 | |||||
| 2025-06-30 | -$1.90M 10-Q · filed 2026-08-12 | $1.80M 10-Q · filed 2026-08-12 | $1.83M 10-Q · filed 2025-08-12 | |||||
| 2025-03-31 | -$3.70M 10-Q · filed 2026-05-13 | $3.71M 10-Q · filed 2025-05-13 | ||||||
| 2024-12-31 | $2.80M 10-K · filed 2026-03-12 | $2.81M 10-K · filed 2025-03-18 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $110.90B derived: sum of 2 quarters · filed 2021-03-01 | -$13.30B derived: sum of 3 quarters · filed 2021-03-01 | -$75.67M 10-K · filed 2021-03-01 | ||||
| 2020-09-30 | $110.90B derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$13.30B derived: sum of 2 quarters · filed 2020-11-09 | -$75.67M 10-Q · filed 2020-11-09 | $2.48B derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2020-06-30 | -$124.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$110.98B 10-Q · filed 2020-08-10 | -$108.42B derived: sum of 3 quarters · filed 2020-08-10 | |||||
| 2020-03-31 | $13.22B 10-Q · filed 2020-05-11 | $15.78B derived: sum of 2 quarters · filed 2020-05-11 | ||||||
| 2019-12-31 | $2.55B derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $1.76M 10-K · filed 2020-03-12 | ||||||
| 2019-09-30 | -$2.55B 10-Q · filed 2019-11-12 | |||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$229.00K derived: sum of 2 quarters · filed 2019-03-12 | -$489.00K derived: sum of 3 quarters · filed 2019-03-12 | -$361.00K 10-K · filed 2019-03-12 | ||||
| 2018-09-30 | -$229.00K 10-Q · filed 2018-11-08 | -$489.00K derived: sum of 2 quarters · filed 2018-11-08 | -$361.00K 10-Q · filed 2018-11-08 | -$941.00K derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2018-06-30 | -$260.00K 10-Q · filed 2018-08-07 | -$132.00K 10-Q · filed 2018-08-07 | -$712.00K derived: sum of 3 quarters · filed 2019-03-12 | -$1.14M derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2018-03-31 | $128.00K 10-Q · filed 2018-05-09 | -$452.00K derived: sum of 2 quarters · filed 2019-03-12 | -$875.00K derived: sum of 3 quarters · filed 2019-03-12 | -$562.00K derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-12-31 | -$580.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$1.00M derived: sum of 2 quarters · filed 2019-03-12 | -$690.00K derived: sum of 3 quarters · filed 2019-03-12 | -$807.00K 10-K · filed 2019-03-12 | ||||
| 2017-09-30 | -$423.00K 10-Q · filed 2018-11-08 | -$110.00K derived: sum of 2 quarters · filed 2018-11-08 | -$227.00K 10-Q · filed 2018-11-08 | -$871.00K derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-06-30 | $313.00K 10-Q · filed 2018-08-07 | $196.00K 10-Q · filed 2018-08-07 | -$448.00K derived: sum of 3 quarters · filed 2019-03-12 | -$451.00K derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2017-03-31 | -$116.00K 10-Q · filed 2018-05-09 | -$761.00K derived: sum of 2 quarters · filed 2019-03-12 | -$764.00K derived: sum of 3 quarters · filed 2019-03-12 | -$656.00K derived: sum of 4 quarters · filed 2019-03-12 | ||||
| 2016-12-31 | -$645.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$648.00K derived: sum of 2 quarters · filed 2019-03-12 | -$540.00K derived: sum of 3 quarters · filed 2019-03-12 | -$134.00K 10-K · filed 2019-03-12 | ||||
| 2016-09-30 | -$3.00K 10-Q · filed 2017-11-08 | $105.00K derived: sum of 2 quarters · filed 2017-11-08 | $511.00K 10-Q · filed 2017-11-08 | $718.00K derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-06-30 | $108.00K 10-Q · filed 2017-08-08 | $514.00K 10-Q · filed 2017-08-08 | $721.00K derived: sum of 3 quarters · filed 2018-03-14 | $105.00K derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2016-03-31 | $406.00K 10-Q · filed 2017-05-10 | $613.00K derived: sum of 2 quarters · filed 2018-03-14 | -$3.00K derived: sum of 3 quarters · filed 2018-03-14 | $20.00K derived: sum of 4 quarters · filed 2018-03-14 | ||||
| 2015-12-31 | $207.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | -$409.00K derived: sum of 2 quarters · filed 2018-03-14 | -$386.00K derived: sum of 3 quarters · filed 2018-03-14 | -$722.00K 10-K · filed 2018-03-14 | ||||
| 2015-09-30 | -$616.00K 10-Q · filed 2016-11-09 | $616.00K 10-Q · filed 2015-11-09 | -$593.00K derived: sum of 2 quarters · filed 2016-11-09 | -$929.00K 10-Q · filed 2016-11-09 | $929.00K 10-Q · filed 2015-11-09 | -$1.73M derived: sum of 4 quarters · filed 2017-03-15 | ||
| 2015-06-30 | $23.00K 10-Q · filed 2016-08-08 | $313.00K 10-Q · filed 2016-08-08 | -$313.00K 10-Q · filed 2015-08-10 | -$1.11M derived: sum of 3 quarters · filed 2017-03-15 | -$938.00K derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2015-03-31 | -$290.00K 10-Q · filed 2016-05-09 | $290.00K 10-Q · filed 2015-05-11 | -$1.14M derived: sum of 2 quarters · filed 2017-03-15 | -$961.00K derived: sum of 3 quarters · filed 2017-03-15 | $439.00K derived: sum of 4 quarters · filed 2017-03-15 | |||
| 2014-12-31 | -$847.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$671.00K derived: sum of 2 quarters · filed 2017-03-15 | $729.00K derived: sum of 3 quarters · filed 2017-03-15 | -$516.00K 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | $176.00K 10-Q · filed 2015-11-09 | -$176.00K 10-Q · filed 2014-11-10 | $1.58M derived: sum of 2 quarters · filed 2015-11-09 | $331.00K 10-Q · filed 2015-11-09 | -$331.00K 10-Q · filed 2014-11-10 | $6.88M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-06-30 | $1.40M 10-Q · filed 2015-08-10 | $155.00K 10-Q · filed 2015-08-10 | $200.00K 10-Q · filed 2014-08-11 | $6.70M derived: sum of 3 quarters · filed 2016-03-14 | $41.60M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2014-03-31 | -$1.20M 10-Q · filed 2015-05-11 | $1.20M 10-Q · filed 2014-05-12 | $5.30M derived: sum of 2 quarters · filed 2016-03-14 | $40.20M derived: sum of 3 quarters · filed 2016-03-14 | $43.40M derived: sum of 4 quarters · filed 2016-03-14 | |||
| 2013-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $41.40M derived: sum of 2 quarters · filed 2016-03-14 | $44.60M derived: sum of 3 quarters · filed 2016-03-14 | $46.10M 10-K · filed 2016-03-14 | $46.08M 10-K · filed 2014-03-17 | |||
| 2013-09-30 | $34.90M 10-Q · filed 2014-11-10 | $38.10M derived: sum of 2 quarters · filed 2014-11-10 | $39.60M 10-Q · filed 2014-11-10 | $36.21M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-06-30 | $3.20M 10-Q · filed 2014-08-11 | $4.60M 10-Q · filed 2014-08-11 | $1.31M derived: sum of 3 quarters · filed 2015-03-16 | $2.41M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2013-03-31 | $1.40M 10-Q · filed 2014-05-12 | -$1.89M derived: sum of 2 quarters · filed 2015-03-16 | -$787.00K derived: sum of 3 quarters · filed 2015-03-16 | $2.61M derived: sum of 4 quarters · filed 2015-03-16 | ||||
| 2012-12-31 | -$3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$2.19M derived: sum of 2 quarters · filed 2015-03-16 | $1.21M derived: sum of 3 quarters · filed 2015-03-16 | -$2.30M 10-K · filed 2015-03-16 | $2.30M 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $1.10M 10-Q · filed 2013-11-12 | $4.50M derived: sum of 2 quarters · filed 2013-11-12 | $987.00K 10-Q · filed 2013-11-12 | $6.77M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2012-06-30 | $3.40M 10-Q · filed 2013-08-09 | $100.00K 10-Q · filed 2013-08-09 | $138.00K 10-Q · filed 2012-08-09 | $5.67M derived: sum of 3 quarters · filed 2014-03-17 | $5.33M derived: sum of 4 quarters · filed 2014-03-17 | |||
| 2012-03-31 | $3.50M 10-Q · filed 2013-05-10 | $2.27M derived: sum of 2 quarters · filed 2014-03-17 | $1.93M derived: sum of 3 quarters · filed 2014-03-17 | $6.83M derived: sum of 4 quarters · filed 2014-03-17 | ||||
| 2011-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | -$1.57M derived: sum of 2 quarters · filed 2014-03-17 | $3.33M derived: sum of 3 quarters · filed 2014-03-17 | -$8.83M 10-K · filed 2014-03-17 | $8.80M 10-K · filed 2013-03-18 | |||
| 2011-09-30 | -$347.00K 10-Q · filed 2012-11-07 | $4.55M derived: sum of 2 quarters · filed 2012-11-07 | -$7.60M 10-Q · filed 2012-11-07 | |||||
| 2011-06-30 | $4.90M 10-Q · filed 2012-08-09 | $7.20M 10-Q · filed 2012-08-09 | ||||||
| 2010-12-31 | $2.40M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |